AlphaValue Corporate Services
This research has been commissioned and paid for by the company and does therefore not constitute an inducement caught by the prohibition under MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things are getting going...hopefully in FY25
Target
Upside 306%
Price (€) 1.78
Market Cap (€M) 80.0
Perf. 1W: -5.41%
Perf. 1M: -15.1%
Perf. 3M: -15.5%
Perf Ytd: -19.7%
10 day relative perf. to stoxx600: -15.5%
20 day relative perf. to stoxx600: -20.2%
EPS change22/05/2020 16:38

No major changes after the release of the FY19 report

Change in EPS2019 : € -0.49 vs -0.48ns
2020 : € -0.32 vs -0.34ns

No major changes to our forecasts. The only ones come from the integration of the detailed FY19 numbers which marginally impact our forecasts, with hardly any change to our target price.



Updates

15 Dec 20 Financing issue
A double bond issue

21 Sep 20 Earnings/sales releases
Update on the group's business

29 Mar 20 Earnings/sales releases
Meaningless FY19 results and product update

23 Dec 19 Financing issue
Extra-financing to increase visibility

20 Nov 19 Financing issue
A €2.6m non-dilutive issue

10 Sep 19 Earnings/sales releases
H1 19: no surprise

10 Jul 19 Financing issue
Warrants to existing shareholders

19 Jun 19 Latest
A commercial success

.